GIKLY (Grifols) 3-Year Revenue Growth Rate : 13.60% (As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Grifols 3-Year Revenue Growth Rate?

Grifols's Revenue per Share for the three months ended in Dec. 2024 was $1.52.

During the past 12 months, Grifols's average Revenue per Share Growth Rate was 9.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 13.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 7.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Grifols was 51.60% per year. The lowest was -5.60% per year. And the median was 7.90% per year.

Competitive Comparison of Grifols's 3-Year Revenue Growth Rate

For the Drug Manufacturers - General subindustry, Grifols's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grifols's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Grifols's 3-Year Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

Grifols 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Grifols (OTCPK:GIKLY) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Grifols 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Grifols's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (OTCPK:GIKLY) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

GIFOF:USA GIFLF:USA GRFS:USA 1GRF:Italy GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain OZTA:Germany GRF:Austria

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.